• Start
  • Pipeline
  • About us
  • For Investors
  • Mehr
    • Start
    • Pipeline
    • About us
    • For Investors
  • Start
  • Pipeline
  • About us
  • For Investors

Welcome to EvlaBio

 We are a Swiss biotech company focused on the development of drug programs with significant unmet medical needs. Our pipeline consists of robust scientific antibody programs for the treatment of hepatocellular carcinoma (Phase 1 ready) and chronic kidney disease with left ventricular hypertrophy (pre-clinical). 



  



With our unbiased evaluation, and the clear focus on value inflection points with the right combination of talents and processes, we bring drug development to the next level. By reducing costs and shortening time to market, EvlaBio will deliver new drugs to patients faster.

    





Copyright © 2022 EvlaBio AG – All Rights Reserved.

Unterstützt von GoDaddy

  • Start
  • privacy-policy
  • Contact Us

Diese Website verwendet Cookies.

Wir setzen Cookies ein, um den Website-Traffic zu analysieren und dein Nutzererlebnis für diese Website zu optimieren. Wenn du Cookies akzeptierst, werden deine Daten mit denen anderer Nutzer zusammengeführt.

AblehnenAnnehmen